Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Moleculin Biotech Inc MBRX

Healthcare Biotechnology
Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company. The Company has a pipeline of clinical programs for the treatment of tumors and viruses. It has three core technologies and six drug candidates, three of which have shown human activity in clinical trials. Its core technologies consist of Annamycin, WP1066 Portfolio and WP1122 Portfolio. Annamycin is designed to avoid multidrug... see more

Recent & Breaking News (NDAQ:MBRX)

Moleculin Announces Corporate Rebranding and Launch of New Website

PR Newswire April 14, 2022

/C O R R E C T I O N -- Moleculin Biotech, Inc./

PR Newswire April 11, 2022

Moleculin Announces Presentation of Positive Preclinical Annamycin Data at the AACR 2022 Annual Meeting

PR Newswire April 8, 2022

Moleculin Reports Full Year Financial Results and Provides Programs Update

PR Newswire March 25, 2022

Moleculin to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and Hosted by M-Vest

PR Newswire March 23, 2022

Moleculin to Present at the Oppenheimer 32nd Annual Healthcare Conference

PR Newswire March 11, 2022

Moleculin Announces Appointment of Joy Yan, M.D., Ph.D. to Board of Directors

PR Newswire March 1, 2022

Moleculin Provides Annamycin AML Program Update and Outlines Next Steps to Advance Towards Late-Stage Development

PR Newswire February 14, 2022

Moleculin Biotech, Inc. to Present at the Virtual Investor 2022 Top Picks Conference

PR Newswire January 20, 2022

Moleculin Announces Updated Preliminary Safety Data for Annamycin in Its Three Phase 1 Clinical Trials for Acute Myeloid Leukemia and Metastases of Soft Tissue Sarcoma

PR Newswire January 18, 2022

JTC Team to Host Virtual Investor 2022 Top Picks Conference on January 25th, 26th, and 27th

Accesswire January 12, 2022

Moleculin to Present at the H.C. Wainwright BioConnect Conference

PR Newswire January 7, 2022

Moleculin Announces Preliminary Third Cohort Interim Data in Phase 1b/2 Clinical Trial of Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases

PR Newswire December 27, 2021

Moleculin Receives FDA Allowance to Begin a Phase 1 Study of WP1122 for the Treatment of Glioblastoma Multiforme

PR Newswire December 1, 2021

Moleculin Biotech, Inc to Present at the Virtual Investor Roundtable Event

PR Newswire November 12, 2021

Moleculin Reports Third Quarter 2021 Financial Results and Provides Programs Update

PR Newswire November 11, 2021

JTC Team to Host Virtual Investor Roundtable Event on November 16th, 17th, and 18th

Accesswire November 4, 2021

Moleculin Receives Authorization from the Medicines and Healthcare Products Regulatory Agency (MHRA) to Commence Phase 1a Clinical Trial of WP1122 for the Treatment of COVID-19

PR Newswire October 19, 2021

Moleculin Announces Interim Data in Phase 1b/2 Clinical Trial of Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases

PR Newswire October 18, 2021

Moleculin to Present at the 2021 Cantor Virtual Global Healthcare Conference

PR Newswire September 27, 2021